Update information
Minor changes since publication
May 2025: We removed the link to NICE technology appraisal guidance on andexanet alfa (TA697) from the section on anticoagulant reversal in hospital settings because the guidance has been updated and no longer applies to this guideline.
August 2023: We added links to the MHRA safety advice on DOAC reversal and NICE technology appraisal guidance 697 on andexanet alfa to the section on anticoagulant reversal in hospital settings.
November 2020: We clarified our advice in recommendation 1.5.23 on crystalloids and tetrastarches for patients with or without active bleeding.
ISBN: 978-1-4731-1680-1